EP Patent

EP3498270A1 — Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer

Assigned to Urogen Pharma Ltd · Expires 2019-06-19 · 7y expired

What this patent protects

The invention relates to the use of a cell cycle modulator capable of arresting the cell cycle in the S and/or G1 phase for the treatment of cancer of a body cavity. The cell cycle modulator comprises in a first composition comprising a first sustained release composition compone…

USPTO Abstract

The invention relates to the use of a cell cycle modulator capable of arresting the cell cycle in the S and/or G1 phase for the treatment of cancer of a body cavity. The cell cycle modulator comprises in a first composition comprising a first sustained release composition component, such as a thermoreversible hydrogel, and wherein said first composition is administered locally to the body cavity. Administration of the first composition is followed by administration of a second composition comprising at least one anti-cancer agent to the body cavity.

Drugs covered by this patent

Patent Metadata

Patent number
EP3498270A1
Jurisdiction
EP
Classification
—
Expires
2019-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Urogen Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.